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Abstract
Background: Many clinical studies are ultimately not fully published in peer-reviewed journals. Underreporting of clinical
research is wasteful and can result in biased estimates of treatment effect or harm, leading to recommendations that are
inappropriate or even dangerous.
Methods: We assembled a cohort of clinical studies approved 2000–2002 by the Research Ethics Committee of the
University of Freiburg, Germany. Published full articles were searched in electronic databases and investigators contacted.
Data on study characteristics were extracted from protocols and corresponding publications. We characterized the cohort,
quantified its publication outcome and compared protocols and publications for selected aspects.
Results: Of 917 approved studies, 807 were started and 110 were not, either locally or as a whole. Of the started studies, 576
(71%) were completed according to protocol, 128 (16%) discontinued and 42 (5%) are still ongoing; for 61 (8%) there was no
information about their course. We identified 782 full publications corresponding to 419 of the 807 initiated studies; the
publication proportion was 52% (95% CI: 0.48–0.55). Study design was not significantly associated with subsequent
publication. Multicentre status, international collaboration, large sample size and commercial or non-commercial funding
were positively associated with subsequent publication. Commercial funding was mentioned in 203 (48%) protocols and in
205 (49%) of the publications. In most published studies (339; 81%) this information corresponded between protocol and
publication. Most studies were published in English (367; 88%); some in German (25; 6%) or both languages (27; 6%). The
local investigators were listed as (co-)authors in the publications corresponding to 259 (62%) studies.
Conclusion: Half of the clinical research conducted at a large German university medical centre remains unpublished; future
research is built on an incomplete database. Research resources are likely wasted as neither health care professionals nor
patients nor policy makers can use the results when making decisions.
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Introduction
Patients and health professionals should be able to consider and
appraise all the evidence available from medical research in order
to make informed decisions about health issues. Such evidence on
effectiveness and potential harm of health care interventions
comes from interventional and observational studies, published in
original articles and well-conducted systematic reviews summariz-
ing primary studies. It has long been known that only a part of all
clinical studies ultimately reaches the stage of full publication in
peer-reviewed journals [1]. Publication or non-publication of
studies is influenced by factors such as the nature and direction of
their results [2–5]. The prevailing underreporting is wasteful and
can result in biased estimates of treatment effect or harm [6].
Prospective trial registration has become an important measure to
reduce underreporting by revealing studies that remained unpub-
lished and hidden for the public. While Switzerland makes
prospective registration of all human research studies mandatory
from 2014 on (http://www.kofam.ch/en), this is still not the case
in most jurisdictions including the European Union and the USA.
Publication outcome is not only influenced by the direction of
study results but also by characteristics such as study design and
size, funding source or the presence of an international collabo-
ration [7]. Main reasons for non-publication are lack of time or
low priority, results not deemed important enough and journal
rejection [8].
Consequently, only a particular share of the body of evidence is
available to users of research data including other researchers,
health professionals and patients. It is given undue prominence in
the literature. This can lead to treatment recommendations that
are at best inappropriate and at worst dangerous [9]. Selective
publication has been deemed unethical, also from a normative
point of view [10].
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Submission to a research ethics committee (REC) or a funding
agency is the earliest stage at which a planned study is documented
in detail. We set out to assemble an unselected cohort of clinical
studies that were approved by the REC of the University of
Freiburg/Germany (Albert-Ludwigs-Universita¨t). We aimed to
characterize the clinical research being conducted, quantify its
publication outcome and compare study protocols and corre-
sponding publications for selected aspects.
Materials and Methods
Cohort of study protocols
We were granted access to the REC’s files, which included the
protocols of human research studies submitted for ethical
approval, amendments, correspondence and other ancillary
documents. A first analysis based on 299 protocols of studies of
all designs approved in 2000 was published earlier [11]. For the
present analysis, we completed the cohort of study protocols by
adding those approved during the years 2001 to 2002. The
definitive analysis is thus based on the study protocols approved
during the three consecutive years 2000 to 2002. We chose this
time period because it was both accessible in the REC’s archives
and long enough to allow for completion of the included studies. If
a study protocol described two or more sub-studies, we regarded
each as a separate study.
Data collection and definitions
We used a standardised data extraction form (MS Access
2010TM) to collect data on study characteristics from the study
protocols, amendments (if any), the REC’s application forms, and
correspondence including study design, sample size, type of
funding, single-/multicentre status, leading study centre and
domestic/international study status. If conflicting information
was found, we recorded the information of the most recent
document in our database. If the information was not reported in
any of the documents, we classified it as ‘‘unclear’’. Data were
extracted by one investigator. If the investigator in charge could
not decide on how to extract data (e.g. when classifying study
design), the issue was discussed with a second investigator to reach
a consensus. All database entries were cross-checked by a second
investigator.
We classified studies according to their design using an
algorithm established earlier [11]. The categories were as follows:
randomised controlled trials, non-randomised intervention studies,
diagnostic studies, observational studies (incl. cohort, case-control,
cross-sectional studies), uncontrolled studies, or laboratory studies
(i.e. using human tissue or blood e.g. for genetic research). Funding
sources were classified as commercial or non-commercial and
information extracted separately. Commercial funding was
defined as any direct financial support or provision of material
(e.g. of the study drug) by a private for-profit company. We further
extracted whether a private company was involved in the
planning, management or data analysis of the study. We assumed
such involvement if the study protocol was written by its staff or if
one of the authors was affiliated with the company. Non-
commercial funding was defined as financial or other support by
governmental funding agencies, public or private foundations
(unless clearly linked to a private company) or research funds of
hospitals or academic institutions. We further classified studies as
international or domestic. If at least one centre outside Germany
participated in recruitment of participants, the study was
considered international, otherwise domestic. We extracted the
planned overall number of participants to be recruited (study size);
if the protocol indicated a range of values we used the smallest
value. Information on current study status was collected from
correspondence with the applicants or other documents available
to the REC.
Identification of corresponding publications
We systematically searched the following electronic databases
and platforms: Medline (platform Ovid, database Ovid Medli-
neR+Daily Update), Web of Science, Google Scholar, Current
Contents Medizin including content by the publishers Hogrefe,
Karger, Kluwer, Springer and Thieme (combined searches on the
Medpilot platform www.medpilot.de) and the University’s publi-
cation registry (Forschungsdatenbank Freiburg, http://forschdb.
verwaltung.uni-freiburg.de/forschung). For randomised controlled
trials, we also searched the Cochrane Central Register of
Controlled Trials (issues 2/2010 - 4/2011), which contains records
of controlled trials from Medline (quarterly updated), Embase
(annually updated) and those identified by manual searches of
journals that are not indexed in electronic literature databases
[12]. A new search strategy was established for each study protocol
including keywords from the protocol, such as experimental drug,
study name or acronym, studied health condition or names of
applicants. We used variants of search terms (e.g. synonyms) and
additional search terms (e.g. trade names of drugs or devices)
where appropriate. The search strategies were manually adapted
to the specific syntax of each literature database. Searches for the
protocols of the year 2000 were conducted between July 2011 and
January 2012 and included an update of the earlier search
conducted in 2006 [11]. For the protocols of the years 2001 and
2002, the searches were conducted between August 2009 and
January 2010. We retrieved the full text of potentially eligible
publications and set up an electronic library of pdf-documents
linked to our MS Access 2010TM database. If we came across
additional eligible references by other sources (e.g. reference lists of
identified articles), we included them. Disagreements on eligibility
were resolved by discussion and consensus among the authors.
Only articles that contained at least some information on the
study’s objectives, methods and results and were published in a
scientific journal were considered full publications. Review articles
and published conference abstracts were excluded. Full reports of
preliminary results published before completion of recruitment or
data collection as planned were counted as full publications.
Retrieved articles were read in full by one investigator. Key
elements of study design and methods, but also study acronyms
and names of authors, were used as criteria to decide whether the
publication was considered matching a study protocol. Any
uncertainties were discussed in regular group meetings.
In order to complement the electronic searches, we surveyed the
investigators applying to the REC by writing personalised letters.
In an appended questionnaire, we asked them for verification of
the already identified publications and for references of additional
publications we may have missed. We also asked whether the
project (a) had been completed as planned (according to the
protocol), (b) had been discontinued entirely or at the local study
site, or (c) is still ongoing with or without continued recruitment or
data collection. The letters and questionnaires were sent out in
February 2010 and reminder letters in May 2010. Undeliverable
letters were sent out again if the investigators’ new address could
be determined.
Based on the information from the survey, we checked and
updated our publication database by deleting wrongly attributed
references and adding any new. We also considered information
on the current project status from other sources such as
correspondence between the REC and investigators and informa-
tion from publications. If the information from the survey did not
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match with what was reported in the publication and could not be
clarified otherwise, we used the information from the publication.
If we found a corresponding publication by our electronic
searches, but received no response in the survey, we used the
publication to determine the study’s status.
Data analyses
We used queries in MS Access 2010 and tabulation in Microsoft
Excel 2010 to obtain standard descriptive statistics. We calculated
the proportion of published study protocols (i.e. the proportion of
studies that had been started at the local study site and resulted in
at least one corresponding full publication), as well as its binomial
95% confidence interval. We used Pearson’s x2 test to examine
associations between study characteristics and publication propor-
tion and calculated McNemar odds ratios for disclosure of funding
information in pairs of protocols and publications of commercially
and non-commercially funded trials [13]. All comparisons were
pre-planned. A p-value of 0.05 was used as threshold for statistical
significance. For agreement of funding information between
protocols and publications, we calculated Cohen’s kappa values
with 95% confidence intervals [14].
Results
Between 2000 and 2002 the REC of the University of Freiburg
approved 981 study protocols containing information on 990
individual studies (Figure 1). Seven protocols comprised two sub-
studies and one comprised three sub-studies; we counted each sub-
study separately. We excluded 73 studies because they were either
duplicate submissions from several participating centres or the
study was rejected, retracted or an extension of a previous study.
Our final dataset comprised 917 approved studies.
Characteristics of included studies
Almost half of the submitted studies were randomised controlled
trials, which was the most frequent study design (408 studies,
45%). Of those, most were of parallel design (364 studies, 89%)
with two treatment arms (269 studies) or three or more treatment
arms (95 studies). Twenty-eight studies (7%) had a cross-over
design and 16 (4%) another variant design, such as factorial or
intra-individual comparison. The second most frequent study
design were uncontrolled studies (186 studies, 20%), such as case
series or uncontrolled phase I/II studies, followed by laboratory
studies using human tissue or blood (138 studies, 15%), non-
randomised intervention studies (72 studies, 8%), cross-sectional
studies (42 studies, 5%), diagnostic studies (41 studies, 4%),
comparative cohort studies (23 studies, 2%), case-control studies (6
studies, 1%), and one health services research study (0.1%)
(Table 1).
The planned sample size was stated in 878 studies (96%) and
ranged from 3 to 9300 participants (median, 120). The planned
duration of enrolment was specified for 382 (42%) studies and
ranged from less than 1 month to 120 months (median, 12
months). 383 studies (42%) planned recruitment in a single centre
and 534 (58%) in multiple centres. Of the multi-centre studies, 310
(58%) included an international collaboration and 221 (41%) a
collaboration with other centres in Germany. Eighty-three multi-
centre studies (15%) were led by the local investigators and 448
(84%) by other study centres in Germany or abroad. For three
studies, the collaboration status and leadership role remained
unclear. Of the 221 domestic studies, 49 (22%) were led by the
investigators in Freiburg and 171 (77%) by another study centre in
Germany. For two studies (one international, one domestic), the
leading centre was not determined at the time of REC submission
and for one international study there was no intention to define a
leading centre (all three grouped as unclear in Table 1).
Commercial funding was present in 422 studies (46%) according
to protocol information (Table 1). In 60 of those, the sponsor
provided study drugs or other material, but was not involved in
study conduct otherwise. Information on non-commercial funding
was given for 140 studies (15%), including applications for funding
by the German Research Foundation (Deutsche Forschungsge-
meinschaft) in 51 studies and the Federal Government (Ministry of
Education and Research/Bundesministerium fu¨r Bildung und
Forschung; Federal Ministry of Health/Bundesministerium fu¨r
Gesundheit) in 26 studies.
Course of studies and publication outcome
In the survey, we obtained responses for 825 of 917 approved
studies (response rate 90%). Including information from other
sources, the project status could be determined for 856 studies
(93%): 807 (88%) were started at the local study site and 110 (12%)
were not started, either locally or in all study centres (Figure 1). Of
the 807 initiated studies, 576 (71%) were completed according to
protocol, 128 (16%) discontinued and 42 (5%) still ongoing at the
time of our study. The latter included studies that were still
recruiting participants (n = 23), were ongoing after completed
recruitment (n = 12) or were ongoing after completed data
collection (n= 7). For 61 (8%) there was no information about
current status and we assumed that they had been started, at least.
We identified 782 full publications that corresponded to 419 of
the 807 studies. The year of publication ranged from 2000 to
2011. Consequently, the overall publication proportion was 52%
(95% CI: 0.48–0.55). The median number of publications per
study was 1 and the range was 1 to 56. Of the 807 initiated studies,
135 (17%) had more than one corresponding publication. Of note,
one laboratory study was still ongoing eight years after ethical
approval and had yielded a total of 56 publications until then. In
the 770 initiated studies with information about the number of
participants (not available for 37), it was planned to recruit at least
298,242 study participants overall (i.e. at all study sites). Of those,
178,254 (60%) participants had their data reported in publications
corresponding to the 419 study protocols. In turn, 119,988 (40%)
persons participated in the 388 studies that ultimately remained
unpublished.
The publication proportion ranged from 40% (95% CI: 0.25–
0.57) in cross-sectional studies to 58% in diagnostic studies (95%
CI: 0.41–0.74) (Table 1). However, the differences by study design
did not reach statistical significance (p= 0.253). In a post-hoc
analysis we combined randomized and non-randomized interven-
tional studies; the publication proportion was 56% (95% CI: 0.51–
0.61). In contrast, in observational studies (combining cohort,
cross-sectional and case-control studies) it was 42% (95% CI:
0.29–0.54). We further analysed whether study size, single or
multi-centre status and type of funding were associated with full
publication. Larger studies and multi-centre studies were more
likely to be published than smaller studies and single-centre
studies, respectively (both comparisons: p = 0.012) (Table 1).
In the group of multi-centre studies, the publication proportion
of international studies (63%; 95% CI: 0.57–0.68) was higher than
of domestic studies (46%; 95% CI: 0.39–0.53; p = 0.00052).
Studies with any funding declared in the protocol (56%; 95% CI:
0.51–0.60) were more often published than studies without (46%;
95% CI: 0.40–0.52; p = 0.021). Thirty-two (63%) of the 51 studies
funded by the German Research Foundation and 12 (46%) of 26
studies funded by the federal government were published.
Of the 419 studies with subsequent publications, evidence of
commercial funding was present in the protocols of 203 (48%) and
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in the corresponding publications of 205 (49%) (Table 2). For most
of these studies (339; 81%), information on presence or absence of
commercial funding was in agreement between protocol and
publications. Cohen’s kappa was 0.62 (95% CI: 0.54–0.69).
However, in 80 (19%) comparisons the funding status did not
match: Commercial funding stated in the protocol was not
Figure 1. Flowchart of study protocols approved between 2000 and 2002 by the research ethics committee of the University of
Freiburg/Germany with number and study status of included studies.
doi:10.1371/journal.pone.0087184.g001
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reported in any of the corresponding publications for 39 studies. In
turn, commercial funding reported in publications was not stated
in the protocol for 41 studies (Table 2). Consequently, the ratio of
counts of discordant pairs (McNemar odds ratio) was 1.05 (95%
CI: 0.66–1.67).
Analogously, evidence of non-commercial funding was present
in the protocols of 75 (18%) studies and in corresponding
publications of 147 (35%) (Table 3). For most of the 419 studies
(315; 75%), information on presence or absence of non-
commercial funding was in agreement between protocol and
publications. Cohen’s kappa was 0.39 (95% CI: 0.28–0.49). In 104
Table 1. Publication status and characteristics of included studies.
Study characteristics Approved (column %) Started at local study site Of those started:
Published (row %) Not published (row %)
Total 917 (100) 807 419 (52) 388 (48)
Study design
Randomised controlled trial 408 (45) 355 201 (57) 154 (43)
Non-randomised intervention study 72 (8) 65 33 (51) 32 (49)
Diagnostic study 41 (4) 36 21 (58) 15 (42)
Cohort study 23 (2) 19 8 (42) 11 (58)
Case-control study 6 (1) 6 3 (50) 3 (50)
Cross-sectional study 42 (5) 40 16 (40) 24 (60)
Uncontrolled study 186 (20) 163 75 (46) 88 (54)
Laboratory study 138 (15) 122 61 (50) 61 (50)
Health services research 1 (,1) 1 1 (100) 0
Pearson x2 (df 8) = 10.173, p = 0.253
Study size
Size$median of 120 449 (49) 391 224 (57) 167 (43)
Size,median of 120 429 (47) 379 177 (47) 202 (53)
Unclear 39 (4) 37 18 (49) 19 (51)
Pearson x2 (df 2) = 8.808, p = 0.012
Collaboration
Single-centre study 383 (42) 340 159 (47) 181 (53)
Multi-centre study 534 (58) 467 260 (56) 207 (44)
Pearson x2 (df 1) = 6.257, p = 0.012
Only multi-centre studies:
International 310 (58) 276 173 (63) 103 (37)
Domestic 221 (41) 189 87 (46) 102 (54)
Unclear 3 (,1) 2 0 2 (100)
Pearson x2 (df 2) = 15.124, p = 0.00052
Leading centre:
Local 83 (15) 76 41 (54) 35 (46)
Other 448 (84) 388 218 (56) 170 (44)
Unclear* 3 (,1) 3 1 (33) 2 (67)
Pearson x2 (df 2) = 0.74, p = 0.691
Funding (as stated in protocol)
Commercial 422 (46) 368 203 (55) 165 (45)
Non-commercial 140 (15) 131 75 (57) 56 (43)
No funding stated 355 (39) 308 141 (46) 167 (54)
Pearson x2 (df 2) = 7.695, p = 0.021
Only commercially funded studies:
Sponsor involved 362 (86) 318 182 (57) 136 (43)
Sponsor not involved 60 (14) 50 21 (42) 29 (58)
Pearson x2 (df 1) = 4.053, p = 0.044
*For two studies (one international, one domestic), the leading centre was not determined at the time of REC submission and for one international study there was no
intention to define a leading centre.
doi:10.1371/journal.pone.0087184.t001
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(25%), the non-commercial funding status did not match: Non-
commercial funding stated in the protocol was not reported in
publications for 16 studies, and non-commercial funding reported
in publications was not stated in the protocol for 88 studies
(Table 3); the McNemar odds ratio was 5.50 [95% CI: 3.21–
10.04]. In 40 publications (and none of the protocols) there was a
statement of both commercial and non-commercial funding.
The predominant language of the publications was English: 367
(88%) studies were published in English and 25 (6%) in German.
This predominance was found in both international and domestic
studies, as well as multi and single centre studies (Table 4).
We analysed whether local investigators (i.e. those submitting to
the REC) were authors of subsequent publications. In 259 (62%) of
the published 419 studies, local investigators were (co-)authors of
at least one corresponding publication (Table 4). All but one
publication from single-centre studies were authored by a local
investigator. In this one publication, an expanded European data
set was reported and the local investigator was acknowledged.
Publications of 101 (39%) multi-centre studies were authored by a
local investigator. In the subgroup of international multi-centre
studies this proportion was 34% (Table 4). In multi-centre studies
led by the local centre, the local investigators were authors in most
studies (35; 85%), but less often (65; 30%) if the study was led by
another centre.
Discussion
We analysed clinical research projects approved by a German
REC over three years, focusing on their publication outcome and
the consistency of reporting in aspects such as funding. Only about
half of the clinical studies that started recruiting participants were
published as full articles about eight to ten years later. Study design
was not associated with full publication. Multicentre status,
presence of an international collaboration, large sample size,
declared study funding and involvement of sponsor as stated in the
protocol were positively associated with subsequent publication.
The Helsinki Declaration of the World Medical Association
emphasizes that both authors and publishers of scientific research
have ethical obligations and that negative and inconclusive results
should be made publicly available, as is the case for positive results
[15]. Our study confirms earlier evidence that the underreporting
of clinical research is still prevalent [16]. It is sometimes put
forward that more rigorous studies (e.g. randomised trials) will be
published eventually while studies conducted with less methodo-
logical rigour may remain ‘in the file drawer’. In our cohort, study
design was not associated with full publication; 43% of randomised
trials had not been published.
It must be of concern that sizeable proportions of studies remain
unpublished. Withholding research results pose several ethical
problems since participants consent on the premise of contributing
to the advancement of medical knowledge and considerable
research resources are invested without any benefit in return. In
our study, research results of almost 120,000 study participants
remained hidden. Not only are patients who are willing to
contribute to medical progress betrayed, but also public funds
wasted. For instance, 19 of the 51 studies (37%) funded by the
German Research Foundation and 14 of the 26 studies (54%)
funded by the German federal government remained unpublished.
Furthermore, non-publication and selective reporting of research
results have an impact on the scientific knowledge. For instance,
the conclusions of systematic reviews may be biased [17].
Information on sources of funding is important to appraise the
validity of a study’s results. It has been shown that commercially
funded studies are more likely to produce favourable results and
conclusions than those sponsored by other sources [18]. Although
this information was consistent for most published studies, it is of
concern that, firstly, for several studies with commercial funding or
non-commercial funding, this information was omitted in the
publications and, secondly, that funding sources are not always
disclosed to the REC (provided that they are known at the time of
submission). The discrepancy regarding funding information is
consistent with our earlier finding in a sub-sample of randomised
trials from the same cohort: There were important discrepancies in
the eligibility criteria for trial participants between protocols and
publications [19]. The present analysis found that commercial
funding information was undisclosed in protocols and publications
Table 2. Funding status in protocols and corresponding publications - commercial funding.
Information in publication, number of studies
Yes No Total
Information in protocol, number of studies Yes 164 39 203
No 41 175 216
Total 205 214 419
doi:10.1371/journal.pone.0087184.t002
Table 3. Funding status in protocols and corresponding publications - non-commercial funding.
Information in publication, number of studies
Yes No Total
Information in protocol, number of studies Yes 59 16 75
No 88 256 344
Total 147 272 419
For protocols with two or more corresponding publications we regarded funding status as reported if it was found in at least one publication.
For publications with both commercial and non-commercial funding, both components were compared separately.
doi:10.1371/journal.pone.0087184.t003
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to the same extent. In contrast, the odds of finding information
about non-commercial funding in the publication (but not the
protocol) was 5.5 times higher than vice versa. A potential
explanation is that industry involvement in the study’s planning
and conduct had already been determined at the time of writing of
most commercially funded protocols, while in non-commercially
funded trials, e.g. investigator-initiated trials, funding requests
might be pending at this stage and consequently no funding
information added to the protocol. Another reason may be that
the publishing journals have strict policies for disclosure that incite
investigators of non-commercially funded trials to disclose their
funding sources more frequently.
Unsurprisingly, our results also show that most studies are
published in English, even if the studies are domestic, multi- or
single-centre studies with funding from a non-anglophone country,
such as Germany. Given that language barriers continue to exist,
in particular if new knowledge is to be transferred from research
into practice, this must be of great concern. Likely, a sizable part of
the healthcare communities not speaking English will not benefit
from research findings reported in English language; concomitant
efforts to provide translations (e.g. of summaries) are therefore
needed [20,21].
The problem of poorly reported or unreported study results has
long been recognised, but is by far not resolved. Clinical trial
registries can help to improve transparency and to inform patients,
physicians and researchers about planned, ongoing and completed
studies [22]. However, prospective registration is not mandatory
for all types of clinical studies and the regulations differ between
countries. In the United States ‘‘applicable clinical trials’’, such as
those on drugs, biological products and devices, have to be
registered since 2007 (http://clinicaltrials.gov/ct2/manage-recs/
fdaaa). In the European Union, clinical drug trials submitted to the
European Medicine Agency (EMA) are registered in the EudraCT
database, but only part of the information is open to the general
public.
In Germany, trial registration is still optional and had not yet
been introduced at the time of REC approval of the included
trials. Therefore, we did not focus on this aspect in the present
study. Analyses of more recent research will be able to address the
impact of trial registration on publication outcomes more
thoroughly.
The lack of access to key data of clinical trials has been put on
the agenda of science policy makers and the public again by the
recent ‘‘All Trials’’ initiative. This international initiative calls on
governments, regulators and research bodies to implement
measures to achieve that ‘‘all trials past and present should be
registered, and the full methods and the results reported’’ (http://
www.alltrials.net). Another recent effort called Restoring Invisible
and Abandoned Trials (RIAT), calls on funders and investigators
to publish or republish studies that were abandoned and left
unpublished. The RIAT proposal provides authors with a set of
criteria to assist with precise publication and republication of
abandoned studies [23,24]. Our empirical data underpins these
efforts suggesting that the magnitude of underreporting has not
diminished yet, despite joint large-scale initiatives such as trial
registration.
Our comprehensive literature search employed several data-
bases and was complemented by an investigator survey with a high
response rate. We are confident that most full articles correspond-
ing to the included study protocols could be identified. Despite
these efforts, we cannot rule out that some were missed.
Consequently, the publication proportion may be underestimated.
On the other hand, we regarded several discontinued studies with
published preliminary results as fully published, which could be
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perceived as an overestimation of the publication proportion. We
excluded conference abstracts and other so-called ‘grey literature’
because those publications are often not indexed in electronic
databases (in particular, abstracts of smaller conferences). Many of
them are not found even by extensive literature searches and
resulting estimates of publication outcome would therefore likely
be incomplete or even biased. Further, we had to rely on several
arbitrary definitions when extracting data and classifying studies.
Since we included all types of studies submitted for ethical
approval, we classified protocols by study design using a
classification scheme that had proven useful in previous studies
[7,11]. Arguably, other criteria could have been used. For clinical
trials, we decided against using the phase I to IV classification
since it was not applied consistently in the included protocols.
Alternative definitions would have been possible also for other
study variables. However, given that all variables were defined a
priori we are confident that our choices did not lead to any
systematic error in our analyses. Clearly, it would be interesting to
analyse more recent study protocols, as the quality of protocols
and publications and the practices of scientific reporting change
over time. In particular, trial registration has been introduced
more widely since then. However, sufficient time must have
elapsed before the ultimate fate of studies with regard to
completion and publication can be determined. The obvious
dilemma is that including more recent protocols would have left
insufficient time for studies to be completed and results to be
published [25]. In our sample, about five percent of studies were
still ongoing eight to ten years after ethical approval. We chose to
analyse the period from REC approval to publication because
reliable data for both these time points were available. An estimate
of the time elapsed between completion of the study (e.g. end of
data collection) and publication would have been more meaning-
ful. However, such information was not included regularly in study
reports or REC files.
It would also have been interesting to investigate the reasons for
non-publication. However, based on our prior experience with
approaching local investigators for empirical research, we deemed
that it is not feasible in a postal survey (in particular up to 10 years
later) as it implies asking sensitive questions and likely would have
influenced the response rate negatively. In fact, in many cases,
non-publication of research has to do with poor project
management, disagreements in research groups or other unfore-
seen events, and it is unlikely that trialists would have disclosed
such circumstances in a survey.
We used a sample of studies conducted in various disciplines at a
large German university. Many were multi-centric, international
or both and studies could be included without seeking the trialists’
consent. We are therefore confident that our results have some
external validity in similar clinical research environments in other
high-income countries.
Conclusion
In a large unselected sample of clinical research projects
approved by a German research ethics committee, only about half
of the started studies were published. In addition, 16% of the
started studies were discontinued. Crucial information such as
study funding differed between protocols and publications in about
20% of published trials. If only part of the accumulated research
data are accessible for those potentially interested, scarce research
resources are wasted. Furthermore, health care professionals and
patients cannot make decisions based on all the available evidence
and other researchers may build future projects on an incomplete
or even biased database.
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